HRP20190096T1 - Molekule analoga ciklosporina modificirani na amino kiselini 1 i 3 - Google Patents

Molekule analoga ciklosporina modificirani na amino kiselini 1 i 3

Info

Publication number
HRP20190096T1
HRP20190096T1 HRP20190096TT HRP20190096T HRP20190096T1 HR P20190096 T1 HRP20190096 T1 HR P20190096T1 HR P20190096T T HRP20190096T T HR P20190096TT HR P20190096 T HRP20190096 T HR P20190096T HR P20190096 T1 HRP20190096 T1 HR P20190096T1
Authority
HR
Croatia
Prior art keywords
amino acid
molecules modified
analogue molecules
cyclosporine analogue
cyclosporine
Prior art date
Application number
HRP20190096TT
Other languages
English (en)
Croatian (hr)
Inventor
Alexander Hegmans
Bruce W. Fenske
Dan J. Trepanier
Mark D. Abel
Shin Sugiyama
Daren R. Ure
Original Assignee
Contravir Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contravir Pharmaceuticals, Inc. filed Critical Contravir Pharmaceuticals, Inc.
Publication of HRP20190096T1 publication Critical patent/HRP20190096T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • C07K7/645Cyclosporins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
HRP20190096TT 2010-12-15 2011-12-14 Molekule analoga ciklosporina modificirani na amino kiselini 1 i 3 HRP20190096T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42357610P 2010-12-15 2010-12-15
EP11848865.9A EP2651965B1 (en) 2010-12-15 2011-12-14 Cyclosporine analogue molecules modified at amino acid 1 and 3
PCT/CA2011/050773 WO2012079172A1 (en) 2010-12-15 2011-12-14 Cyclosporine analogue molecules modified at amino acid 1 and 3

Publications (1)

Publication Number Publication Date
HRP20190096T1 true HRP20190096T1 (hr) 2019-02-22

Family

ID=46243924

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190096TT HRP20190096T1 (hr) 2010-12-15 2011-12-14 Molekule analoga ciklosporina modificirani na amino kiselini 1 i 3

Country Status (25)

Country Link
US (2) US9200038B2 (enExample)
EP (2) EP3461835A1 (enExample)
JP (3) JP6144627B2 (enExample)
KR (3) KR20190002731A (enExample)
CN (2) CN103443119B (enExample)
AU (1) AU2011342284C1 (enExample)
BR (1) BR112013014890B1 (enExample)
CA (1) CA2821009C (enExample)
DK (1) DK2651965T3 (enExample)
ES (1) ES2705750T3 (enExample)
HR (1) HRP20190096T1 (enExample)
HU (1) HUE042490T2 (enExample)
IL (1) IL226792A (enExample)
LT (1) LT2651965T (enExample)
MX (1) MX353720B (enExample)
MY (2) MY192981A (enExample)
NZ (1) NZ611620A (enExample)
PH (1) PH12013501213A1 (enExample)
PL (1) PL2651965T3 (enExample)
PT (1) PT2651965T (enExample)
RU (1) RU2630690C9 (enExample)
SG (2) SG191069A1 (enExample)
SI (1) SI2651965T1 (enExample)
TR (1) TR201900128T4 (enExample)
WO (1) WO2012079172A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
AU2011342284C1 (en) * 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
CN104487449A (zh) * 2012-06-01 2015-04-01 阿勒根公司 环孢菌素a类似物
WO2014132084A1 (en) * 2013-03-01 2014-09-04 Ucl Business Plc Non-immunosuppressive cyclosporin derivatives as antiviral agents
CA2921961A1 (en) * 2013-08-26 2015-03-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
JP2019518745A (ja) * 2016-05-17 2019-07-04 エス アンド ティー グローバル インク. 新規シクロスポリン誘導体及びその使用
US20180193003A1 (en) 2016-12-07 2018-07-12 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018106928A1 (en) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
US11523772B2 (en) 2016-12-14 2022-12-13 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
TW201902507A (zh) 2017-04-14 2019-01-16 美商康特維爾製藥公司 治療病毒感染之組合療法
EP3612540A1 (en) 2017-04-20 2020-02-26 Rising Tide Foundation Triphenylphosphonium-tethered tetracycyclines for use in treating cancer
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CA3110250A1 (en) 2018-08-22 2020-02-27 Bacainn Therapeutics, Ltd. Cyclosporine compositions and methods of use
CN115427060A (zh) 2020-02-19 2022-12-02 海必恩制药公司 环孢菌素类似物用于治疗纤维化的用途
TW202140057A (zh) * 2020-02-25 2021-11-01 美商希皮恩製藥公司 環孢素類似物於治療癌症之用途
CN115335389A (zh) 2020-03-26 2022-11-11 睿诺医疗科技(上海)有限公司 亲环蛋白抑制剂及其用途
CN115315432A (zh) * 2020-03-26 2022-11-08 睿诺医疗科技(上海)有限公司 亲环蛋白抑制剂及其用途
US20220168385A1 (en) * 2020-11-29 2022-06-02 Hepion Pharmaceuticals, Inc. Use of cyclosporine analogues as antithrombotic agents
CN113173974B (zh) * 2021-03-18 2024-09-06 北京大学深圳研究生院 环孢素衍生物的合成方法
CN115677533B (zh) * 2021-07-30 2023-12-05 沈阳化工研究院有限公司 一种4-庚基苯甲腈的制备方法
IT202300001116A1 (it) * 2023-01-25 2024-07-25 Indena Spa Processo per la preparazione di un intermedio utile per la sintesi di voclosporina
TW202502801A (zh) * 2023-06-02 2025-01-16 大陸商睿諾醫療科技(上海)有限公司 親環蛋白抑制劑及其用途
WO2024254480A2 (en) * 2023-06-08 2024-12-12 Hepion Pharmaceuticals, Inc. Solid state forms of rencofilstat

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210581A (en) 1975-11-04 1980-07-01 Sandoz Ltd. Organic compounds
CH614931A5 (enExample) 1975-11-04 1979-12-28 Sandoz Ag
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
DE2819094A1 (de) 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
SE448386B (sv) 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
AU548156B2 (en) 1980-02-14 1985-11-28 Novartis Ag Cyclo sporin
US4396542A (en) 1980-02-14 1983-08-02 Sandoz Ltd. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
EP0056782B1 (en) 1981-01-09 1984-08-01 Sandoz Ag Novel cyclosporins
CH667274A5 (de) 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
JPS6182786A (ja) 1984-09-28 1986-04-26 ブラザー工業株式会社 ミシン
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4764503A (en) 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4885276A (en) 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
ES2059558T3 (es) 1987-06-17 1994-11-16 Sandoz Ag Ciclosporins y su uso como productos farmaceuticos.
ATE110784T1 (de) 1987-06-19 1994-09-15 Sandoz Ag Zyklische peptolide.
EP0373260B1 (en) 1987-06-22 1994-03-09 Merck & Co. Inc. Cyclosporin derivatives with modified "8-amino acid"
GB8717300D0 (en) 1987-07-22 1987-08-26 Nat Res Dev Cyclosporins
US5227467A (en) 1987-08-03 1993-07-13 Merck & Co., Inc. Immunosuppressive fluorinated cyclosporin analogs
US4914188A (en) 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US5236899A (en) 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
JPH04502328A (ja) 1988-12-05 1992-04-23 ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク シクロスポリンaの新規誘導体、それに対する抗体及びその使用
US5604092A (en) 1988-12-05 1997-02-18 The Trustees Of Columbia University In The City Of New York Method for the detection of HIV-1 using a cyclosporine-specific monoclonal antibody that reacts with the P24 Gag protein
US5284826A (en) 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5122511A (en) 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5214130A (en) 1990-02-27 1993-05-25 Merck & Co., Inc. Synthesis of novel immunosuppressive cyclosporin analogs with modified amino acids at position-8
ES2095926T5 (es) 1990-11-02 2001-02-16 Novartis Ag Cyclosporins.
GB9204466D0 (en) 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
WO1997011092A1 (en) 1994-04-07 1997-03-27 Nippon Shinyaku Co., Ltd. Cyclosporin phosphate derivatives and medicinal composition
US5639852A (en) 1994-09-01 1997-06-17 Wisconsin Alumni Research Foundation Immunostimulatory agents
US5948693A (en) 1994-09-01 1999-09-07 Wisconsin Alumni Research Foundation Solid phase synthesis of immunosuppressive agents
JPH08148407A (ja) 1994-11-21 1996-06-07 Nikon Corp 照明光学装置
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
MY114711A (en) 1995-06-06 2002-12-31 Pfizer Substituted n-(indole-2-carbonyl)-b-alanmamides and derivatives as antidiabetic agents
US5948884A (en) * 1995-07-17 1999-09-07 C-Chem Ag Cyclosporin derivatives with anti-HIV effect
JP3089350B2 (ja) 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2762843B1 (fr) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
US6270957B1 (en) 1997-08-26 2001-08-07 Wisconsin Alumni Research Foundation Non-Imuunosuppressive cyclosporins and their use in the prevention and treatment of HIV infection
AU9203898A (en) 1997-08-26 1999-03-16 Wisconsin Alumni Research Foundation Cyclosporin a conjugates and uses therefor
AU750245B2 (en) 1997-10-08 2002-07-11 Aurinia Phamaceuticals Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US5990274A (en) 1997-11-25 1999-11-23 Dade Behring Inc. Cyclosporine derivatives and uses thereof
FR2772768B1 (fr) 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
HUP0102833A3 (en) 1998-06-12 2002-03-28 Chem Ag C Cyclosporins, process for preparation thereof and their use
FR2780061B1 (fr) 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
WO2000001715A1 (fr) 1998-07-01 2000-01-13 Debiopharm S.A. Nouvelle cyclosporine ayant un profil d'activite ameliore
US6790935B1 (en) 1999-02-05 2004-09-14 Debiopharm S.A. Cyclosporin derivatives and method for the production of said derivatives
JP2003514000A (ja) 1999-11-19 2003-04-15 エル・ジー ハウスホールド アンド ヘルスケア リミティッド シクロスポリン誘導体含有毛髪成長促進剤
US6521595B1 (en) 1999-11-19 2003-02-18 Lg Chemical, Ltd. Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
KR20020039528A (ko) 2000-11-22 2002-05-27 조명재 사이클로스포린 7- 티오아미드 유도체를 유효성분으로하는 모발성장촉진제
KR100360716B1 (ko) 2000-11-22 2002-11-13 주식회사 엘지생활건강 사이클로스포린 에이 7- 티오아미드 유도체를유효성분으로 하는 모발성장촉진제
KR100681670B1 (ko) 2001-02-14 2007-02-09 주식회사 엘지생활건강 [감마 히드록시 엔- 메틸-엘-루신9]사이클로스포린 에이를유효성분으로 하는 모발 성장 촉진제
US6784156B2 (en) 2001-03-05 2004-08-31 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of respiratory diseases
CN1507451A (zh) 2001-04-20 2004-06-23 �±Ȱ·�ķ�ɷ����޹�˾ 可用作前体药物的修饰环孢菌素及其应用
KR100465012B1 (ko) 2001-05-11 2005-01-13 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
KR100695611B1 (ko) 2001-05-17 2007-03-14 주식회사 엘지생활건강 [감마 히드록시 엔-메틸 엘-루신4] 사이클로스포린유도체를 유효성분으로 하는 모발 성장 촉진제
US20030087813A1 (en) 2001-10-12 2003-05-08 Or Yat Sun Cyclosporin analogs for the treatment of lung diseases
US6809077B2 (en) 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
BRPI0213658A8 (pt) 2001-10-19 2016-12-06 F Hoffmann La Roche Ltd Método para preparar uma mistura isomérica predeterminada ou não dos análogos de ciclosporina a modificados no resíduo de 1-aminoácido, métodopara produzir uma mistura enriquecida com e-isômero ou com z-isômero de análogos de ciclosporina a modificados no resíduo de 1-aminoácido, mistura de (e) e (z)-isômeros, composição, método para a síntese estereoseletiva do z-isômero de isatx247, método para a preparação de aldeído do ciclosporina a
ES2310604T3 (es) 2001-10-19 2009-01-16 Isotechnika, Inc. Mezclas de analogos de ciclosporinas y su uso como agentes inmunomoduladores.
CN1274294C (zh) 2001-10-19 2006-09-13 伊索泰克尼卡股份有限公司 环孢菌素类似物微乳液预浓缩物
US6987090B2 (en) 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR100641295B1 (ko) * 2002-11-11 2006-10-31 김성수 사이클로필린의 항산화제로서의 용도 및 사이클로필린의과발현에 의해 세포이식에서 사이클로스포린 a에 의해유발되는 세포독성의 방지
US20040110666A1 (en) 2002-12-04 2004-06-10 Or Yat Sun Cyclosporins for the treatment of immune disorders
US7012065B2 (en) 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
JP2006524232A (ja) 2003-03-17 2006-10-26 アルバニー モレキュラー リサーチ インコーポレーティッド 新規サイクロスポリン
ITMI20030627A1 (it) 2003-03-31 2004-10-01 Polimeri Europa Spa Polimeri vinilaromatici espandibili e procedimento per la loro preparazione.
TW200505946A (en) 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
WO2004089940A1 (en) * 2003-04-11 2004-10-21 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
US20040266669A1 (en) 2003-06-20 2004-12-30 Wu Frank X. H. Cyclosporin derivatives for the treatment of immune disorders
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
DE102004011988A1 (de) 2004-03-11 2005-09-22 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Cyclosporinderivate und diese enthaltende pharmazeutische Zusammensetzungen
US20060015374A1 (en) 2004-07-19 2006-01-19 Yanhong Ochs Risk management on the application of crop inputs
CA2575280C (en) 2004-07-29 2012-08-14 Amr Technology, Inc. Novel processes for stereoselective synthesis of trans isatx 247
US20060035821A1 (en) 2004-08-16 2006-02-16 Hunt Kevin W Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
US7226906B2 (en) 2004-08-16 2007-06-05 Array Biopharma, Inc. Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
EP1809656A4 (en) 2004-09-29 2009-03-25 Amr Technology Inc CYCLOSPORINAL KINANALOGA AND ITS PHARMACEUTICAL APPLICATIONS
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
DK1802650T3 (da) 2004-10-01 2012-02-06 Scynexis Inc 3-ether- og 3-thioether-substituerede cyklosporinderivater til behandling og forebyggelse af hepatitis C-infektion
JP2008515886A (ja) 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
US7696167B2 (en) 2004-11-22 2010-04-13 Astellas Pharma Inc. Cyclic peptide compound
US20060223743A1 (en) * 2004-12-17 2006-10-05 Mark Abel Metabolites of cyclosporin analogs
US8329658B2 (en) 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
US20070232532A1 (en) 2006-03-28 2007-10-04 Amr Technology, Inc. Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
BRPI0915552A2 (pt) * 2008-07-10 2017-06-20 Allergan Inc derivados de ciclosporina, seu uso e sua composição farmacêutica
MX2011001152A (es) * 2008-07-30 2011-06-09 Isotechnika Pharma Inc Moleculas de analogo de ciclosporina no-inmunesupresoras.
EP2391376A4 (en) 2009-01-30 2012-08-01 Enanta Pharm Inc ANALOGUES OF CYCLOSPORIN FOR PREVENTING OR TREATING HEPATITIS C INFECTION
US20100305047A1 (en) * 2009-05-27 2010-12-02 Allergan, Inc. Cyclosporin derivatives for enhancing the growth of hair
AU2010339460A1 (en) * 2009-12-30 2012-07-19 Scynexis Inc. Cyclosporine analogues
CN103261212A (zh) * 2010-10-12 2013-08-21 阿勒根公司 环孢菌素类似物
WO2012051194A1 (en) * 2010-10-12 2012-04-19 Allergan, Inc. Cyclosporin analogs
AU2011342284C1 (en) * 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3

Also Published As

Publication number Publication date
SI2651965T1 (sl) 2019-03-29
SG191069A1 (en) 2013-07-31
SG10201510236XA (en) 2016-01-28
HK1243633A1 (zh) 2018-07-20
NZ611620A (en) 2016-02-26
EP2651965B1 (en) 2018-12-12
PH12013501213A1 (en) 2016-12-16
AU2011342284A1 (en) 2013-07-18
KR102305423B1 (ko) 2021-09-27
DK2651965T3 (en) 2019-02-18
KR20200029639A (ko) 2020-03-18
CN107496902B (zh) 2022-01-18
EP2651965A1 (en) 2013-10-23
CA2821009C (en) 2019-03-05
KR20130124515A (ko) 2013-11-14
BR112013014890B1 (pt) 2023-10-24
MX2013006831A (es) 2014-10-14
AU2011342284B2 (en) 2017-02-16
ES2705750T3 (es) 2019-03-26
EP2651965A4 (en) 2017-08-09
JP6831259B2 (ja) 2021-02-17
RU2630690C2 (ru) 2017-09-12
RU2630690C9 (ru) 2017-12-28
JP6144627B2 (ja) 2017-06-07
AU2011342284C1 (en) 2017-07-13
MX353720B (es) 2018-01-25
US9200038B2 (en) 2015-12-01
MY165152A (en) 2018-02-28
CA2821009A1 (en) 2012-06-21
KR102011339B1 (ko) 2019-08-16
WO2012079172A1 (en) 2012-06-21
MY192981A (en) 2022-09-20
TR201900128T4 (tr) 2019-02-21
US9714271B2 (en) 2017-07-25
CN103443119A (zh) 2013-12-11
EP3461835A1 (en) 2019-04-03
CN107496902A (zh) 2017-12-22
JP2019123712A (ja) 2019-07-25
US20140142033A1 (en) 2014-05-22
JP2017128577A (ja) 2017-07-27
LT2651965T (lt) 2019-01-10
US20160207961A1 (en) 2016-07-21
IL226792A (en) 2017-10-31
RU2013127162A (ru) 2015-06-10
PT2651965T (pt) 2019-01-28
CN103443119B (zh) 2017-09-22
KR20190002731A (ko) 2019-01-08
BR112013014890A2 (pt) 2020-08-04
PL2651965T3 (pl) 2019-04-30
JP2014505035A (ja) 2014-02-27
HUE042490T2 (hu) 2019-07-29

Similar Documents

Publication Publication Date Title
SG10201510236XA (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
ZA201207331B (en) Concentrated protein formulations and uses thereof
IL229353B (en) Dolestatin derivatives related to unnatural amino acids and medicinal preparations that include them
IL222961A0 (en) Novel dna-dinding proteins and uses thereof
SI2391620T1 (sl) Z alkilaminom substituiran dicianopiridin in njegova predzdravila estra amino kisline
IL248880A0 (en) Preparations containing r-g-cysteic acid peptides and their uses
IL230918A0 (en) Modified proteins and peptides
GB201010557D0 (en) RNA molecules and uses thereof
EP2408802A4 (en) CYCLIC AMINO ACID MOLECULES AND THEIR METHODS OF SYNTHESIS
PL2588491T3 (pl) Nowy peptyd i jego zastosowanie
ZA201003681B (en) Compositions and methods comprising basic amino acid peptides and proteases
IL188681A0 (en) Pharmaceutical compositions and methods utilizing a d-amino acid
ZA201106665B (en) Products comprising n-phenylpropenoyl amino acid amides and uses thereof
EP2593595A4 (en) NOVEL PEPTIDES AND USES THEREOF
IL232867A0 (en) Preparations of bacteriophage gene 3 protein and use as amyloid binding agents
PL2627668T3 (pl) Peptydy i ich zastosowanie
PL2464656T3 (pl) Nowy peptyd i jego zastosowanie
ZA201305485B (en) Plant protein hydrolysates
ZA201100019B (en) Variant hhip1 protein and methods and uses thereof
EP2398490A4 (en) MODIFICATIONS OF PEPTIDES FROM CUPREDOXIN AND METHODS OF USE
EP2668958A4 (en) CASPOFUNGIN ANALOGS AND APPLICATIONS THEREOF
IL219182A0 (en) 2-amino-3-methyl-hex-5-enoic acid and its use in the production of peptides such as bacitracins
PL392256A1 (pl) N-(Bisfosfonometylo)lizyny oraz sposób ich wytwarzania
IL218428A0 (en) Multi-site modified sp1 ploypeptides and uses thereof
GB201121233D0 (en) Modified proteins and peptides